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Phosphoproteomic screening identifies
physiological substrates of the CDKL5 kinase
Ivan M Muñoz1,†, Michael E Morgan1,†, Julien Peltier1,2, Florian Weiland1, Mateusz Gregorczyk1,
Fiona CM Brown1, Thomas Macartney1, Rachel Toth1, Matthias Trost1,2,* & John Rouse1,**
Abstract
Mutations in the gene encoding the protein kinase CDKL5 cause a
debilitating neurodevelopmental disease termed CDKL5 disorder.
The impact of these mutations on CDKL5 function is poorly under-
stood because the substrates and cellular processes controlled by
CDKL5 are unclear. Here, we describe a quantitative phosphopro-
teomic screening which identified MAP1S, CEP131 and DLG5—
regulators of microtubule and centrosome function—as cellular
substrates of CDKL5. Antibodies against MAP1S phospho-Ser900
and CEP131 phospho-Ser35 confirmed CDKL5-dependent phospho-
rylation of these targets in human cells. The phospho-acceptor
serine residues in MAP1S, CEP131 and DLG5 lie in the motif RPXSA,
although CDKL5 can tolerate residues other than Ala immediately
C-terminal to the phospho-acceptor serine. We provide insight into
the control of CDKL5 activity and show that pathogenic mutations
in CDKL5 cause a major reduction in CDKL5 activity in vitro and in
cells. These data reveal the first cellular substrates of CDKL5, which
may represent important biomarkers in the diagnosis and treat-
ment of CDKL5 disorder, and illuminate the functions of this poorly
characterized kinase.
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Introduction
Cyclin-dependent kinase-like 5 (CDKL5/STK9) is a poorly under-
stood protein kinase mutated in human disease. CDKL5 mutations
were first described in 2003 in two girls affected by infantile spasms
(Kalscheuer et al, 2003). Some of the symptoms associated with
CDKL5 mutations overlap with Rett syndrome (RTT) caused by
mutations in MECP2, which has resulted in some of the patients
with CDKL5 mutations being classified as having an early-onset
seizure variant of RTT (ESV-RTT). Other patients with mutations in
CDKL5 have been variably classified as having early infantile epilep-
tic encephalopathy, X-linked dominant infantile spasm syndrome or
diagnosed with other epileptic conditions (Tao et al, 2004). Now,
however, a distinct condition referred to as CDKL5 disorder has
been recognized as an independent clinical entity, with early-onset
epilepsy and severe neurodevelopmental delays as defining hall-
marks. In particular, CDKL5 disorder is characterized by seizure
onset before 3 months of age, severely impaired gross motor,
language and hand skills and subtle but shared physical characteris-
tics (Fehr et al, 2013). Over 800 cases of CDKL5 disorder have been
reported worldwide, and this number is increasing as awareness of
CDKL5 disorder grows (Krishnaraj et al, 2017).
The CDKL5 gene is found on the X chromosome, and several
transcript isoforms have been reported although the major isoform
appears to be 1,030 amino acid long (CDKL5115; Hector et al, 2016;
Fig 1A). The vast majority of patients with CDKL5 disorder are
female, with a spectrum of severities that is most likely related to
the pattern of X-inactivation, which is known to be random. The
condition is more severe in male than in female presumably because
there is no wild-type CDKL5 in affected individuals (Fehr et al,
2013). The CDKL5 gene product belongs to the CMGC branch of the
human kinome and more specifically to a sub-branch comprising
kinases CDKL1, 2, 3, 4 and 5 (Manning et al, 2002). These kinases
are so-called because of similarity in the kinase domain to cyclin-
dependent kinases (CDKs) although they are also highly similar to
MAP kinases (MAPKs; data not shown). Phosphorylation of MAPKs
and CDKs in the well-characterized activation T-loop, a variable
region between catalytic subdomains VII and VIII, is a common
mechanism activating these kinases (Cobb & Goldsmith, 1995; Roux
& Blenis, 2004; Lolli & Johnson, 2005). In some kinases, T-loop
phosphorylation is achieved by autophosphorylation, but often, it is
catalysed by upstream kinases. For example, the classical MAPKs
termed ERK1 and ERK2 are inactive before MAP kinase kinase 1-
catalysed phosphorylation of Thr183 and Tyr185 in each T-loop; these
residues lie in a TEY motif, and phosphorylation of both residues is
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required for ERK1 activity (Anderson et al, 1990; Cobb & Goldsmith,
1995; Roux & Blenis, 2004). Human CDKL5 has a TEY motif in the
T-loop, and it has been proposed that this motif in CDKL5 is recog-
nized by phospho-specific antibodies raised against the ERK1 TEY
motif, although it was not demonstrated that cross-reactivity with
CDKL5 requires an intact TEY motif (Lin et al, 2005; Bertani et al,
2006). The sites of phosphorylation and autophosphorylation on
CDKL5 in cells have not yet been mapped, and the mechanisms
controlling kinase activity are unknown.
Although a range of proteins have been described as potential
substrates of CDKL5, the proteins phosphorylated by CDKL5 in cells
remain to be identified, and no systematic screen for cellular CDKL5
substrates has been reported. Identification of the key substrates of
CDKL5 is vital, as this information would illuminate the major cellu-
lar functions of this kinase and may provide biomarkers that would
aid the diagnosis and treatment of CDKL5 disorder. Being able to
measure CDKL5 activity in cells would also allow unambiguous
assessment of the functional impact of pathogenic mutations on
CDKL5, most of which map to the kinase catalytic domain (Fig 1A).
In this study, we report the results of a global phosphoproteomic
screening for CDKL5 substrates, which revealed the first physiologi-
cal substrates of CDKL5 that in turn has allowed us to test the effect
of pathological mutations on CDKL5 function, and enabled us to
obtain the first clues as to how CDKL5 activity is controlled in cells.
Results
TMT-based CDKL5 phosphoproteomic screening
To identify CDKL5 substrates, we undertook a quantitative phos-
phoproteomic screening, which compared the total phosphopro-
teomes of CDKL5 knockout (KO) cells and CDKL5 KO cells in which
CDKL5 was stably re-expressed. We chose this strategy to avoid
clonal differences between knockout cells and parental cells. First,
CRISPR-/Cas9-mediated genome editing was used to disrupt the
CDKL5 gene in U2OS osteosarcoma cells modified with the Flp-InTM
T-RExTM system. Around 35 clones were screened for CDKL5 loss by
Western blotting using in-house CDKL5 antibodies (data not
shown); two of the knockout clones (clones 7 and 13) are shown in
Fig 1B. Genomic sequencing and RT–PCR revealed that clone 7 had
no wild-type CDKL5 allele (data not shown), but instead, two
different classes of disrupted CDKL5 allele were identified that result
in truncation at amino acids 62 and 75, respectively (Appendix Fig
S1A and B). No wild-type CDKL5 allele was detected in clone 13
(data not shown), and instead, a single class of disrupted CDKL5
allele was identified bearing a mutation that truncates the protein
product at residue Val38 (Appendix Fig S1C and D). The Flp-InTM T-
RExTM system allows stable, tetracycline (Tet)-inducible expression
of a gene of interest from a specific genomic location. The CDKL5
open reading frame was introduced at the FRT sites of CDKL5
knockout (KO) clone 13. Incubation of these cells with Tet allowed
stable expression of CDKL5 (Fig 1C; data not shown).
Three biological replicates of CDKL5 KO cells stably transfected
with empty vector or CDKL5 KO cells stably expressing CDKL5 were
lysed, cysteines were reduced and alkylated, and protein extracts
were digested with trypsin. Phosphopeptides were enriched using
titanium dioxide (TiO2) chromatography, and the six samples were
isotopically labelled using tandem mass tags (TMT; Fig 1D). TMT
labelling allowed quantitative, multiplexed analysis of all six
samples, which were combined and analysed in a parallel manner
that enables quantitation of tryptic peptides in each of the individual
samples with high accuracy (Rauniyar & Yates, 2014). Labelling effi-
ciency was checked in each sample and found to exceed 95%.
Samples were pooled and fractionated by basic pH reversed-phase
chromatography into 40 fractions which were concatenated into 12
fractions. These fractions were analysed by LC-MS/MS on a high-
resolution Orbitrap Fusion mass spectrometer (Fig 1D). A total of
12,316 unique phosphosites were quantified in all replicates at a
false-discovery rate (FDR) of < 1%. Data showed high levels of
reproducibility between replicates (Appendix Fig S2A and B). A total
of 194 phosphosites were higher in abundance in CDKL5-expressing
cells compared with CDKL5 KO cells (> 1.5-fold, P < 0.05), repre-
senting potential CDKL5 substrates, whereas 159 were lower in
abundance (Fig 2A; Dataset EV1). Only 29 of the 194 phosphosites
that were higher in CDKL5-expressing cells compared with CDKL5
KO cells were threonine-phosphorylated, all on Thr-Pro (TP) motifs
(Appendix Fig S3A), whereas the majority (165) were serine-phos-
phorylated. The phosphosites changing the most were sites of
CDKL5 itself: Ser306, Ser308, Ser407, Ser529 and Ser543 (Fig 2A;
Dataset EV1). Even though these sites lie in Ser-Pro (SP) motifs typi-
cally phosphorylated by CDKs and MAPKs, the most highly enriched
phospho-motif in the mass spectrometry dataset was RXXS (5.11-
fold increase; Appendix Fig S3B). This motif was found in the
▸Figure 1. A quantitative phosphoproteomic approach for the identification of cellular CDKL5 targets.A Pathogenic and non-pathogenic CDKL5 variants. Schematic diagram shows modular domains in CDKL5 and the position of amino acid substitutions in humans that
are either pathogenic, non-pathogenic or of unknown consequence according to RettBASE (http://mecp2.chw.edu.au/cdkl5/cdkl5_variant_list_copy.php; Krishnaraj
et al, 2017). NES: nuclear export signal; NLS: nuclear localization signal.
B Generation of CDKL5 knockout human cells. U2OS cells modified with the Flp-InTM T-RExTM system were subjected to genome editing to disrupt CDKL5. Extracts of cells
from two different knockout (KO) clones (7 and 13) were subjected to SDS–PAGE on the gel types indicated followed by immunoblotting with in-house anti-CDKL5
antibodies. “Hi” higher exposure; “lo” lower exposure. Asterisk: non-specific band.
C Stable expression of CDKL5 in knockout clone 13. The CDKL5 open reading frame (1,030 amino acid/115-kDa isoform) was inserted at the FRT sites in CDKL5 knockout
clone 13 from (B). Cells transfected with empty vector were used as control. Cells were incubated with the indicated concentrations of tetracycline (Tet), and extracts
were immunoblotted with anti-CDKL5 antibodies.
D Phosphoproteomics workflow. CDKL5 knockout clone 13 and the same cells re-expressing CDKL5 were lysed and protein extracts were digested using trypsin. After
phosphopeptide enrichment by TiO2 chromatography, peptides were isotopically labelled by TMT and combined. Combined peptides were fractionated by high-pH
reversed-phase chromatography. Fractions were separated on a nano-HPLC and analysed by quantitative mass spectrometry on an Orbitrap Fusion mass
spectrometer. Data were analysed using MaxQuant software.
Source data are available online for this figure.
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second and third most highly changing hits from the screen: micro-
tubule-associated protein 1S (MAP1S) Ser900 and CEP131/AZI1
Ser35, respectively (Fig 2B and C). MAP1S Ser900 and CEP131/AZI1
Ser35 both show a high degree of evolutionary conservation among
their respective orthologues (Fig 2B and C). Furthermore, the simi-
larity in sequence around the two phosphorylation sites (MAP1S:
RPLS900A and CEP131: RPGS35A) raised the possibility that CKDL5
may favour serine residues in the sequence RPXSA.
Gene Ontology (GO) analysis showed that the proteins less phos-
phorylated in the absence of CDKL5 were significantly enriched in
protein groups involved in DNA damage response, the actin
cytoskeleton and microtubule-associated proteins (Fig 2D and E).
Interestingly, among these were a number of known proteins
involved in the control of primary cilia—cell surface appendages
nucleated by centrosomes and structured by microtubules (Basten &
Giles, 2013; Fry et al, 2014; Canning et al, 2018), including MAP1S,
CEP131 and DLG5 (Orban-Nemeth et al, 2005; Tegha-Dunghu et al,
2014). Proteins involved in centromere function such as centromere
protein C (CENPC, Ser146) and proteins involved in cytokinesis func-
tions such as nucleolar and spindle-associated protein 1 (NUSAP1,
Ser349/Ser352) were also identified. Taken together, these data
suggest that CDKL5 directly or indirectly controls the cell cytoskele-
ton and/or cilium function, consistent with a recent report that over-
expression of CDKL5 reduces primary cilium length in human cells
(Canning et al, 2018).
Validating CDKL5-dependent phosphorylation of MAP1S
and CEP131
In order to test CDKL5-dependent phosphorylation of MAP1S in
cells, antibodies were raised in sheep against a phosphopeptide
corresponding to the sequence around Ser900. Dot blot analysis
revealed that affinity-purified antibodies from the second and third
bleeds recognized the phosphopeptide immunogen but hardly recog-
nized the non-phosphopeptide equivalent (Fig EV1A). We next
tested whether CDKL5 can phosphorylate MAP1S in cells. To this
end, MAP1S was co-expressed with CDKL5 in HEK293 cells, and the
phosphorylation of MAP1S in anti-FLAG precipitates was examined
using the phospho-Ser900 antibodies. As shown in Fig 3A, expres-
sion of wild-type CDKL5 but not a K42R kinase-dead CDKL5 mutant
markedly increased the phosphorylation of MAP1S. A MAP1S
Ser900Ala mutation prevented cross-reactivity with the phospho-
Ser900 antibodies (Fig 3A), confirming the specificity. Taken
together, these data validate MAP1S as a cellular substrate of
CDKL5. A similar analysis was carried out to test CDKL5-dependent
phosphorylation of CEP131. Affinity-purified antibodies, raised in
sheep against a phosphopeptide corresponding to the sequence
around Ser35, recognized the phosphopeptide immunogen but
hardly recognized the non-phosphopeptide equivalent (Fig EV1B).
As shown in Fig 3B, expression of wild-type CDKL5 but not a
Lys42Arg (K42R) kinase-dead CDKL5 mutant markedly increased the
phosphorylation of FLAG-CEP131. The CEP131 Ser35Ala mutation
prevented cross-reactivity with the phospho-Ser35 antibodies. Taken
together, these data validate CEP131 as a cellular substrate of
CDKL5.
As CDKL5 belongs to a family of five related kinases (Fig EV2A),
we tested the ability of the CDKL5-related kinases CDKL1, 2, 3 and 4
to phosphorylate MAP1S and CEP131. We found that CDKL1 and
CDKL2 only drove very weak phosphorylation of MAP1S in HEK293
cells, and CDKL1 only drove very weak phosphorylation of CEP131
even though the level of expression of CDKL1 and 2 was consider-
ably higher than CDKL5 (Fig EV2B and C). It is worth pointing out
that CDKL1–4 may simply be inactive—or minimally active—under
the conditions used in this study, but perhaps their activity (and
perhaps the activity of all CDKLs) is regulated in response to envi-
ronmental cues or extracellular or intracellular stimuli.
Towards a CDKL5 consensus sequence
We wished to test whether CDKL5 can phosphorylate MAP1S Ser900
and CEP131 Ser35 directly and also to investigate the sequence deter-
minants that influence phosphorylation of these serine residues by
CDKL5. To this end, peptides were synthesized corresponding to the
sequence around MAP1S Ser900 and CEP131 Ser35, and also around
the phosphorylation sites in PDZD4 (pSer230), RASSF7 (pSer159),
AFADIN (pSer217), FERMT2 (pSer192) and NUSAP1 (pThr355) which
were also among the top hits in the phosphoproteomic screening
(Fig 4A). Two lysine residues were added at the N-terminus of each
peptide to enable binding to P81 phosphocellulose paper, which
enabled isolation of peptides at the end of kinase reactions and quan-
titation of peptide phosphorylation (see Materials and Methods
section). As shown in Fig 4B, the MAP1S Ser900 peptide was effi-
ciently phosphorylated by FLAG precipitates from extracts of cells
expressing C-terminally FLAG-tagged CDKL5 but not the FLAG-
CDKL5 K42R kinase-dead mutant. Robust phosphorylation of the
CEP131 Ser35 peptide was also observed, but none of the other
substrate peptides were phosphorylated (Fig 4B). These data indicate
that CDKL5 can phosphorylate Ser900 of MAP1S and Ser35 of CEP131
directly. We also tested the ability of the CDKL5-related kinases
CDKL1, 2, 3 and 4 to phosphorylate the MAP1S Ser900-containing
peptide. As shown in Fig EV2D, FLAG-CDKL2 (but not FLAG-CDKL1,
3 or 4) immunoprecipitated from cells phosphorylated the MAP1S
peptide at around 50% of the efficiency observed for CDKL5,
although CDKL2 expression was significantly higher than CDKL5.
It is interesting to note that MAP1S Ser900 and CEP131 Ser35 both
lie in an Arg-Pro-X-Ser-Ala (RPXSA) motif (Fig 2B and C), whereas
the serine residues in the other putative substrates which were not
phosphorylated directly by CDKL5—PDZD4 (pSer230), RASSF7
◀ Figure 2. Identification of CDKL5 substrates in human cells.A Volcano plot showing potential CDKL5 substrates. The horizontal cut-off line represents a P-value of 0.05, and the vertical cut-off lines represent a log2 ratio of 0.58
(~1.5-fold) above which peptides were considered to differ significantly in abundance between CDKL5 KO cells expressing empty vector and CDKL5 KO cells
expressing CDKL5. The mass spectrometry proteomics data for this figure have been deposited to the ProteomeXchange Consortium via the PRIDE partner
repository (Jarnuczak & Vizcaino, 2017) with the dataset identifier PXD009374.
B, C Sequence alignment of the Ser900 phosphorylation site in MAP1S (B) and the Ser35 phosphorylation site in CEP131 (C), in the species indicated.
D Gene Ontology (GO) term enrichment of phosphopeptides that are more abundant in CDKL5-expressing cells compared to knockout cells.
E String database network analysis of proteins which harbour phosphosites up-regulated in CDKL5-expressing cells compared to knockout cells. These are part of
protein complexes involved in a wide range of biological functions.
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(pSer159), AFADIN (pSer217), FERMT2 (pSer192) and NUSAP1
(pThr355)—do not (Fig 4A). This observation raised the possibility
that the RPXSA motif might represent a consensus sequence for
phosphorylation by CDKL5, and we next set out to investigate the
importance of the determinants that influence serine phosphoryla-
tion by CDKL5. To this end, a range of synthetic peptides was
synthesized, based on the sequence around MAP1S Ser900. The
wild-type peptide sequence was KKRASRPLS900ARSEPSE (Fig 4C),
and we tested the impact of making amino acid substitutions at
Arg897, Pro898, Leu899, Ser900 and Ala901. As shown in Fig 4C, chang-
ing Arg897 to the positively charged residue Lys or the negatively
charged residues Asp or Glu causes a severe reduction in peptide
phosphorylation by CDKL5. Changing Pro898 to Ala, Phe, Gly, Leu
or the aromatic ring-bearing amino acids Tyr or His severely reduces
Ser900 phosphorylation, whereas substituting Leu899, which is the
variable “X” residue in the RPXSA motif, has no effect (Fig 4C). As
expected, changing Ser900 to Ala abolishes peptide phosphorylation
although changing this residue to Thr permits peptide phosphoryla-
tion albeit at around 55% of the Ser-containing peptide. Changing
Ala901 to bulkier residues Val, Ile or Leu causes a severe reduction
in Ser900 phosphorylation, but changing Ala901 to Gly, a small
residue like Ala, permits Ser900 phosphorylation at around 60% of
wild-type levels (Fig 4C).
The data above indicate that the residues at Arg897, Pro898 and
Ala901 are important in allowing CDKL5 to phosphorylate Ser900 of
MAP1S, and they suggest that CDKL5 prefers to phosphorylate Ser
residues in an RPX[S/T][A/G] motif. However, a report in the liter-
ature described robust phosphorylation of AMPH1 on Ser293 by a
recombinant form of the CDKL5 catalytic domain in vitro (Seki-
guchi et al, 2013). AMPH1 Ser293 lies in the sequence RPRS293P,
suggesting that CDKL5 can accommodate a Pro residue C-terminal
to the phosphorylated serine. We investigated this possibility in
two ways. First, we found that CDKL5 can phosphorylate a
synthetic peptide corresponding to the sequence around Ser293 of
AMPH1 (KKPAPVRPRS293PSQTRKG) with an efficiency similar to
the MAP1S Ser900 peptide; substituting Ser293 for alanine abolished
phosphorylation of this peptide (Fig 4D). Second, we found that
substituting Ala901 in the synthetic MAP1S Ser900 peptide for a Pro
residue allowed phosphorylation at around 80% of the wild-type
peptide (Fig 4D). Taken together, these data suggest that the CDKL5
prefers substrates with serines that lie in the motif RPX[S/T][A/G/P]
although it is possible that residues other than Ala/Gly/Pro can be
accommodated C-terminal to the phospho-acceptor serine.
We next mined our original mass spectrometry data for phos-
phopeptides with phosphoserines in the motif RPX[S/T][A/G/P]
that were more abundant in CDKL5-expressing cells than in knock-
out cells (Dataset EV1). In addition to MAP1S and CEP131, this
analysis revealed phosphorylation of Ser1115 of DLG5, a protein
involved in signalling to the microtubule-based cytoskeleton (Liu
et al, 2014; Kwan et al, 2016). To confirm that CDKL5 can phos-
phorylate DLG5 Ser1115 in cells, FLAG-tagged human DLG5 was co-
expressed with untagged CDKL5 (wild type or a K42R kinase-dead
mutant) or empty vector in HEK293 cells. Extracts were subjected
to immunoprecipitation with anti-FLAG antibodies, and phosphory-
lation site analysis was carried out by extracted ion chromatograms
(XIC) analysis of the phosphopeptide containing Ser1115. FLAG-
MAP1S and FLAG-CEP131 were analysed in parallel as positive
controls. As shown in Fig 5A and B, FLAG-DLG5 was more highly
phosphorylated on Ser1115 when co-expressed with wild-type
CDKL5, than with the kinase-dead equivalent or empty vector, and
the change in DLG5 phosphorylation was comparable to that seen
with MAP1S Ser900 and CEP131 Ser35 (Fig 5C–F). Furthermore,
CDKL5 phosphorylated a synthetic peptide based on the sequence
around DLG5 Ser1115 even more robustly than the MAP1S Ser900
peptide, and as expected, substituting Arg1112, Pro1113 or Ala1116
severely reduced DLG5 peptide phosphorylation efficiency
(Fig EV3). It is interesting to note that DLG5 Ser1115 shows a high
degree of evolutionary conservation among a range of orthologues,
suggesting functional importance (Fig 5G). These data reveal DLG5
as a substrate of CDKL5.
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Figure 3. CDKL5-dependent phosphorylation ofMAP1S andCEP131 in cells.
A CDKL5 phosphorylates MAP1S at Ser900 in human cells. HEK293 cells were
co-transfected with CDKL5 (wild type “WT” or kinase-dead K42R mutant)
and/or FLAG-MAP1S (wild type “WT” or a S900A mutant “SA”). Anti-FLAG
precipitates were subjected to Western blotting with the antibodies
indicated. “Hi” higher exposure; “lo” lower exposure. The input extracts
were also subjected to immunoblotting (lower panels). Three independent
experiments were done, and one representative experiment is shown.
B CDKL5 phosphorylates CEP131 at Ser35 in human cells. HEK293 cells were
co-transfected with CDKL5 (wild type “WT” or kinase-dead K42R mutant)
and/or FLAG-CEP131 (wild type WT or a S35A mutant). Anti-FLAG
precipitates were subjected to Western blotting with the antibodies
indicated. “Hi” higher exposure; “lo” lower exposure. The input extracts
were also subjected to immunoblotting (lower panels). Three independent
experiments were done, and one representative experiment is shown.
Source data are available online for this figure.
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T-loop autophosphorylation controls CDKL5 activity in cells
T-loop phosphorylation is a key mechanism for kinase regulation,
and CDKL5 has a Thr-Glu-Tyr (TEY) motif between catalytic subdo-
mains VII and VIII that in MAPKs and CDKs must be phosphorylated
for activity. Intriguingly, the T169-E-Y171 motif in CDKL5 is preceded
by a conserved Tyr at residue 168 (Fig EV4). In experiments to map
sites of CDKL5 phosphorylation, Tyr171 emerged as a major site of
tyrosine autophosphorylation (data not shown). Consistent with this
idea, FLAG-CDKL5, but not the kinase-dead FLAG-CDKL5 K42R
mutant, cross-reacted with anti-phospho-Tyr antibodies, before and
after preincubation of precipitates with Mg2+-ATP (Fig 6A), and this
was prevented by mutating Tyr171, but not Tyr168 (Fig 6A). These
data suggested that CDKL5 autophosphorylates on Tyr171. To test
this further, antibodies were raised in sheep against a phosphopep-
tide corresponding to the sequence around Tyr171. As shown in
Fig 6B, the affinity-purified antibodies cross-reacted with CDKL5
wild-type and a Tyr168Ala mutant, but not with a Tyr171Ala mutant.
Furthermore, the kinase-inactivating K42R mutation also prevented
CDKL5 Tyr171 phosphorylation. These data strongly suggest that
CDKL5 autophosphorylates on Tyr171 in the T-loop. Surprisingly, we
found that CDKL5 is incapable of phosphorylating Tyr171-containing
synthetic peptides based on the CDKL5 T-loop under conditions
where MAP1S Ser900 is phosphorylated efficiently (Fig 6C). Further-
more, substituting the serine phospho-acceptor residue in the
MAP1S Ser900 synthetic peptide for a tyrosine residue abolished
peptide phosphorylation (Fig 6C). Taken together, these data indi-
cate that although CDKL5 can catalyse intramolecular autophospho-
rylation on Tyr171, it cannot phosphorylate exogenous substrates on
tyrosine.
We next set out to test the effect of mutating Tyr171—and also
Tyr168 and Tyr169 singly and in combination—on CDKL5 activity. To
this end, HEK293 cells were co-transfected with FLAG–MAP1S (wild
type “WT” or Ser900Ala “SA”) and CDKL5 (wild type “WT”, K42R
kinase-dead “KD” mutant or T-loop mutants). FLAG precipitates
were probed with MAP1S pSer900 antibodies. As shown in Fig 6D,
mutating Tyr171 completely abolished CDKL5 activity towards
MAP1S, whereas mutating Tyr168 or Thr169 to A had no apparent
effect. The effect of T-loop mutations on intrinsic CDKL5 activity
in vitro was also examined. As shown in Fig 6E, mutating Tyr171
completely abolished CDKL5 activity towards the MAP1S Ser900-
containing peptide, whereas mutating Tyr168 or Thr169 to A had no
effect. In a similar manner, mutating Tyr171 prevented CDKL5-
dependent phosphorylation of CEP131 on Ser35 in cells and
abolished the activity of CDKL5 towards the CEP131 Ser35-
containing peptide in vitro, whereas mutating Tyr168 or Thr169 to A
had no effect (Fig EV5A and B). Taken together, these data show
that the activity of CDKL5 towards its substrates is critically depen-
dent on autophosphorylation of Tyr171 in the T-loop TEY motif.
Pathogenic mutations reduce CDKL5 activity towards MAP1S
and CEP131
The impact of pathogenic CDKL5 mutations on substrate phospho-
rylation in cells is unclear because the substrates have remained
elusive. We next investigated the impact of pathogenic mutations
on the activity of CDKL5 towards MAP1S. Most of the pathogenic
mutations are located in the kinase catalytic domain (Fig 1A; Krish-
naraj et al, 2017), and we investigated the impact of pathogenic
kinase domain mutations Gly20Asp (Raymond et al, 2013),
Leu64Pro (Fichou et al, 2009), Ile72Thr (Saletti et al, 2009),
Arg178Trp (Nemos et al, 2009) and Gln219Pro (Hagebeuk et al,
2013). We also investigated a series of CDKL5 variants that are
either benign: Gln791Pro (Tao et al, 2004) and Val999Met (Nectoux
et al, 2006) or of uncertain significance: Leu302Phe (Liang et al,
2011), Asn399Thr (Sprovieri et al, 2009), Val718Met (Krishnaraj
et al, 2017) and Val793Ala (Archer et al, 2006; Fig 1A). HEK293
cells were co-transfected with HA-tagged MAP1S and CDKL5 (wild
type “WT”, K42R kinase-dead “KD” or other mutants). Anti-HA
precipitates were probed with MAP1S pSer900 antibodies. As shown
in Fig 7A, CDKL5 pathogenic kinase domain mutations Gly20Asp,
Leu64Pro, Ile72Thr, Arg178Trp, and Gln219Pro caused a severe reduc-
tion in MAP1S Ser900 phosphorylation. In a similar vein, these
mutations caused a major reduction in the activity of FLAG-CDKL5
precipitates towards the synthetic MAP1S Ser900 peptide (Fig 7B).
The Leu302Phe, Asn399Thr, Val718Met, Gln791Pro, Val793Ala and
Val999Met variants that are either benign or of uncertain signifi-
cance to CDKL5 disorder supported wild-type levels of MAP1S
phosphorylation (Fig 7A). Furthermore, these amino acid substitu-
tions did not affect the activity of CDKL5 towards the synthetic
MAP1S Ser900 peptide (Fig 7B).
We also investigated the impact of pathogenic mutations on
the activity of CDKL5 towards CEP131. HEK293 cells were co-
transfected with FLAG-tagged CEP131 and CDKL5 (wild type
“WT”, K42R kinase-dead “KD” or other mutants). Anti-FLAG
precipitates were probed with CEP131 pSer35 antibodies. As
shown in Fig 7C, CDKL5 pathogenic mutations Gly20Asp,
Leu64Pro, Ile72Thr and Gln219Pro caused a severe reduction in
◀ Figure 4. CDKL5 sequence determinants favouring phosphorylation by CDKL5.A Sequence of synthetic peptides surrounding the sites of phosphorylation in putative CDKL5 substrates that were identified in the phosphoproteomic screening. The
amino acid number of the phosphorylated residue in each peptide (highlighted in red) is listed.
B Peptide kinase assays to investigate CDKL5 sequence specificity. Anti-FLAG precipitates from HEK293 cells transiently expressing FLAG-tagged CDKL5 (wild type “WT”
or a K42R kinase-dead “KD” mutant) were incubated with the synthetic peptides from the proteins indicated (sequences shown in A) in the presence of [c-32P]-
labelled ATP-Mg2+, and peptide phosphorylation was measured by Cerenkov counting.
C Same as (B), except that the peptides used were designed specifically to investigate the effect of amino acid substitutions at R897, P898, L899 and A901 on the
phosphorylation of MAP1S Ser900. The RPXSA motif is shaded in blue, and amino acid substitutions compared with the wild-type MAP1S Ser900 peptide are shown in
red.
D Same as (C), except that phosphorylation of the indicated peptides from AMPH1 and MAP1S was compared.
Data information: In (B–D), phosphorylation of the control wild-type MAP1S peptide is taken as 100%. The data are represented as mean  SEM from three independent
experiments.
Source data are available online for this figure.
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CEP131 Ser35 phosphorylation. In a similar vein, these mutations
caused a major reduction in the activity of FLAG-CDKL5 precipi-
tates towards the synthetic CEP131 Ser35 peptide (Fig 7D). In
contrast, the Leu302Phe, Asn399Thr, Val718Met, Gln791Pro,
Val793Ala and Val999Met variants that are either benign or of
uncertain significance to CDKL5 disorder supported wild-type
levels of CEP131 peptide phosphorylation (Fig 7C). Furthermore,
these amino acid substitutions did not affect the activity of
CDKL5 towards the synthetic CEP131 Ser900 peptide (Fig 7D).
Taken together, these data show that CDKL5 mutations causative
of CDKL5 disorder cause a major reduction in CDKL5 activity
towards MAP1S and CEP131. It is interesting to note that muta-
tions Gly20Asp and Leu64Pro cause a severe reduction in CDKL5
autophosphorylation, but the Arg178Trp mutation that abolishes
CDKL5 activity towards MAP1S and CEP131 has no apparent
effect on CDKL5 autophosphorylation (Fig EV6). It is possible
that Arg178 is involved in exogenous substrate binding, which
could account for the discrepancy.
Discussion
In this study, we used state-of-the-art phosphoproteomic screening
to identify, and then validated, the first cellular substrates of
CDKL5: MAP1S, CEP131 and DLG5. The phosphorylated serine in
all three substrates lies in the motif RPXSA, although experiments
with synthetic peptides revealed that substitution of S for T
allowed MAP1S peptide phosphorylation at around 55% of the S-
containing peptide (Fig 4C), and substitution of A for G or P
allowed peptide phosphorylation at around 60 and 90% of the
wild-type sequence, respectively. Therefore, CDKL5 can phospho-
rylate Ser residues that lie in the motif RPX[S/T][A/G/P],
although it is possible that residues other than A/G/P can be
tolerated C-terminal to the phospho-acceptor serine.
It is interesting to note that in phospho-motif analysis SP
motifs in general were highly enriched in the phosphopeptides
that were more abundant in CDKL5-expressing cells
(Appendix Fig S3B). This might not be surprising given that
CDKL5 shows a high degree of similarity in the catalytic domain
with MAPKs and CDKs which phosphorylate target proteins on
[S/T]P motifs. However, it is unlikely that CDKL5 catalyses
direct phosphorylation of targets on SP motifs unless they lie in
an RPXSP motif. Under conditions where CDKL5 can
phosphorylate peptides containing MAP1S Ser900 or CEP131
Ser35, it cannot phosphorylate peptides containing FERMT2
Ser192 or NUSAP1 Thr355 which contain an SP and TP motif,
respectively (Fig 4A and B). Moreover, AMPH1 Ser293 lies in an
RPRSP motif and substituting Arg290 for Lys in the AMPH1
Ser293-containing synthetic peptide abolishes phosphorylation by
CDKL5 (data not shown). Nonetheless, phospho-SP motifs are
more abundant in CDKL5-expressing cells than in CDKL5 knock-
out cells (Dataset EV1), and it may be that CDKL5 influences
the activity of one or more proline-directed kinase, directly or
indirectly. It is interesting to note that all of the phosphorylation
sites identified in our phosphoproteomic analysis in CDKL5 itself
are SP motifs (Fig 2A; Dataset EV1). Preliminary analysis indi-
cates that these are not sites of autophosphorylation, however,
and are instead catalysed by other kinases (data not shown). On
the other hand, CDKL5 appears to autophosphorylate on Tyr171
even though it cannot phosphorylate exogenous substrates on
tyrosine. CDKL5 autophosphorylation appears to be critical for
kinase activity. It will be interesting to investigate the regulation
of CDKL5 T-loop phosphorylation in cells and to explore the
underlying mechanisms.
The substrates of CDKL5 we validated are all involved in
control of the cytoskeleton, suggesting that CDKL5 may regulate
cytoskeletal function. MAP1S is a ubiquitously expressed protein
that can bind to and stabilize microtubules in vitro and in cells
(Orban-Nemeth et al, 2005; Ding et al, 2006; Dallol et al, 2007;
Tegha-Dunghu et al, 2014; Mohan & John, 2015), and depletion
of MAP1S causes mitotic abnormalities (Dallol et al, 2007). It has
been reported that MAP1S bridges microtubules with mitochon-
dria and components of the autophagy machinery, and conse-
quently, cells from Map1s/ mice show decreased levels of
autophagosomal biogenesis and clearance of damaged mitochon-
dria (Xie et al, 2011a,b). The N-methyl-D-aspartate (NMDA)
receptor subunit NR3A also interacts with MAP1S in brain, and
thus, MAP1S might link NR3A to the microtubule cytoskeleton
(Eriksson et al, 2007). In this light, the NMDA receptor-mediated
synaptic response is enhanced in the hippocampus of Cdkl5
knockout mice, and the N2B subunit of the NMDA receptor over-
accumulates in post-synaptic densities of hippocampal neurons in
these mice (Okuda et al, 2017). Furthermore, the enhanced
seizure susceptibility seen in Cdkl5 knockout mice is abrogated
by an NMDA receptor antagonist (Okuda et al, 2017). Intrigu-
ingly, Ser900 in MAP1S lies close to one of two reported
▸Figure 5. Mass spectrometric validation of DLG5 as a CDKL5 substrate.A–F Testing CDKL5-dependent DLG5 phosphorylation in cells. HEK293 cells were co-transfected with FLAG-DLG5 (A, B), FLAG-MAP1S (C, D) or FLAG-CEP131 (E, F) together
with either empty vector (), wild-type CDKL5 (WT) or kinase-dead CDKL5 (K42R). Cells were harvested after 24 h and lysed, and extracts were subjected to
immunoprecipitation with anti-FLAG-agarose beads. Precipitates were resolved by SDS–PAGE and stained with Coomassie Brilliant Blue (COO, top panel). A small
fraction of the precipitates was subjected to Western blotting with anti-FLAG antibodies (A, C). The input extracts were also subjected to immunoblotting with the
antibodies indicated in the lower panels. Three independent experiments were done, and one representative experiment is shown. Coomassie-stained bands as
shown in top panels of (A, C and E) were excised, destained and proteins digested. Peptides were extracted, TMT labelled and analysed using mass spectrometry.
VSN-calibrated and transformed, isotopically corrected reporter ion intensities of the phosphopeptides of interest are plotted in (B, D and F); the outline of the box
plot indicates minimum and maximum values, and the middle line indicates the median. Higher intensity corresponds to higher phosphopeptide abundance in the
relevant sample. Statistical testing was carried out using a t-test (Computer Code EV1; Appendix Fig S4); to account for multiple testing, the significance threshold
was adjusted from a = 0.05 to a = 0.00833 (six t-tests) by Bonferroni correction (Computer Code EV1). All t-tests resulted in a P-value below the adjusted
significance threshold. **P < 0.01; ***P < 0.001. Individual P-values are shown in Table EV3.
G Sequence alignment of the Ser1115 phosphorylation site in DLG5 in the species indicated.
Source data are available online for this figure.
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Figure 6. T-loop autophosphorylation is critical for CDKL5 activity.
A, B Tyr-autophosphorylation of CDKL5. Anti-FLAG precipitates from HEK293 cells transiently expressing FLAG-tagged CDKL5 (wild type “WT” or mutants K42R kinase-
dead “KD”, Y168A,Y171A or both) were subjected to immunoblotting with the antibodies indicated before or after incubation of precipitates with Mg2+-ATP for
30 min at 30°C. Each experiment was done three times, and a representative experiment is shown.
C CDKL5 cannot phosphorylate Tyr-containing synthetic peptides. Anti-FLAG precipitates from HEK293 cells transiently expressing FLAG-tagged CDKL5 (wild type “WT”
or a K42R kinase-dead “KD” mutant) were incubated with the synthetic peptides indicated in the presence of [c-32P]-labelled ATP-Mg2+, and peptide
phosphorylation was measured by Cerenkov counting. Data are represented as mean  SEM from three independent experiments.
D HEK293 cells were co-transfected with untagged CDKL5 (wild type “WT” or the mutants indicated) and FLAG-tagged MAP1S [wild type (WT), a Ser900Ala mutant
(SA)] or empty vector (). Anti-FLAG precipitates were subjected to Western blotting with the antibodies indicated. The input extracts were also subjected to
immunoblotting (lower panels). Each experiment was done three times, and a representative example is shown.
E Anti-FLAG precipitates from HEK293 cells transiently expressing FLAG-tagged CDKL5 (wild type “WT” or the mutants indicated) were incubated with a synthetic
peptide corresponding to the sequence around the MAP1S Ser900 phosphorylation site, in the presence of [c-32P]-labelled ATP-Mg2+. Peptide phosphorylation was
quantitated in a scintillation counter. Data are represented as mean  SEM from three independent experiments.
Source data are available online for this figure.
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Figure 7. Effect of pathogenic CDKL5 mutations on CDKL5 activity.
A HEK293 cells were co-transfected with untagged CDKL5 (wild type “WT” or the mutants indicated) and HA-tagged MAP1S. Anti-HA precipitates were subjected to
Western blotting with the antibodies indicated. The input extracts were also subjected to immunoblotting (lower panels). Three independent experiments were done,
and one representative experiment is shown. Hi, high exposure; lo, low exposure.
B Anti-FLAG precipitates from HEK293 cells transiently expressing FLAG-tagged CDKL5 (wild type “WT” or the mutants indicated) were incubated with a synthetic
peptide corresponding to the sequence around the MAP1S Ser900 phosphorylation site, in the presence of [c-32P]-labelled ATP-Mg2+. Peptide phosphorylation was
quantitated in a scintillation counter. Data are represented as mean  SEM from three independent experiments.
C HEK293 cells were co-transfected with untagged CDKL5 (wild type “WT” or the mutants indicated) and FLAG-tagged CEP131. Anti-FLAG precipitates were subjected to
Western blotting with the antibodies indicated. The input extracts were also subjected to immunoblotting (lower panels). Three independent experiments were done,
and one representative experiment is shown. Hi, high exposure; lo, low exposure.
D Anti-FLAG precipitates from HEK293 cells transiently expressing FLAG-tagged CDKL5 (wild type “WT” or the mutants indicated) were incubated with a synthetic
peptide corresponding to the sequence around the CEP131 Ser35 phosphorylation site, in the presence of [c-32P]-labelled ATP-Mg2+. Peptide phosphorylation was
quantitated in a scintillation counter. Data are represented as mean  SEM from three independent experiments.
Source data are available online for this figure.
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microtubule-binding domains (Orban-Nemeth et al, 2005; Ding
et al, 2006; Dallol et al, 2007). From this point of view, it is
possible that MAP1S Ser900 phosphorylation by CDKL5 alters the
microtubule-binding capacity of MAP1S which could in turn
impact on the trafficking of mitochondria, or neurotransmitter-
containing vesicles or the NMDA receptor, for example, in a way
required to prevent neuronal deterioration in CDKL5 disorder.
CEP131 is a centrosomal protein which has been implicated in
the formation and function of primary cilia. In this light, depletion
of CEP131 from human epithelial cells causes reduced ciliogenesis
and defects in cilial morphogenesis (Graser et al, 2007). CEP131
depletion was also reported to cause reduced proliferation rate,
centriole amplification, chromosomal instability and DNA damage
(Staples et al, 2012). Intriguingly, CEP131 was reported to be phos-
phorylated by the stress-inducible MK2 kinase in response to UV
light on both Ser47 and Ser78. Phosphorylation of CEP131 on these
residues leads to 14-3-3 binding, sequestration of CEP131 in the
cytosol away from centrosomes, and abolishes stress-induced centri-
olar satellite reorganization (Villumsen et al, 2013; Tollenaere et al,
2015). Ser35 targeted by CDKL5 lies close to the MK2 phosphoryla-
tion sites and may therefore impact on stress-induced centriolar
satellite reorganization or other aspects of centriolar and cilial func-
tion. It is interesting to note that Drosophila and zebrafish lacking
the relevant CEP131 orthologue show phenotypes reminiscent of
human ciliopathies (Andersen et al, 2003; Wilkinson et al, 2009;
Ma & Jarman, 2011). Ciliopathies in humans are most commonly
associated with retinal and renal problems, which are not associated
with CDKL5 disorder, and therefore, it is unlikely that CDKL5 disor-
der is a ciliopathy. However, a subset of ciliopathies affect the brain
and cause seizures—juvenile myoclonic epilepsy, for example.
Intriguing connections between CDKL5 and primary cilia have been
reported. CDKL5 (LF5p) controls ciliary length in Chlamydomonas
(Tam et al, 2013), and human CDKL5 localizes to cilia and impairs
ciliogenesis when overexpressed (Canning et al, 2018). It will be
important to test cilium function in CDKL5 knockout cells and in the
context of pathogenic mutations, and to check the impact of CDKL5-
mediated phosphorylation of CEP131.
There are several interesting applications made possible by the
identification of the first cellular substrates of CDKL5. Firstly, phos-
pho-MAP1S and phospho-CEP131 antibodies can be used as
biomarkers of CDKL5 activity. This will enable experiments to screen
for stimuli that activate CDKL5, for example, and will allow the
effectiveness of new treatments for CDKL5 disorder to be tested—
gene replacement therapy and drugs that promote reading through
nonsense mutations, for example. A major limitation, however, is
that better antibodies will be required to allow analysis of the phos-
phorylation of endogenous MAP1S and CEP131. Recent identifi-
cation of the Rab proteins as targets of the Parkinson’s disease
kinase LRRK2 required the development of rabbit monoclonal anti-
bodies to allow analysis of endogenous Rab phosphorylation in
biological samples (Steger et al, 2017; Lis et al, 2018). Our data
demonstrate for the first time that pathogenic mutations in CDKL5
are loss of function in that they inhibit phosphorylation of MAP1S
and CEP131. Highly sensitive phospho-specific antibodies may allow
screening for small molecules, or genes that when deleted by
genome editing rescue the phosphorylation of MAP1S and CEP131
phosphorylation in CDKL5-defective cells. Such an endeavour may
pave the way for new therapies to treat CDKL5 disorder.
Materials and Methods
All DNA constructs and antibodies generated for the present study,
and datasheets for each plasmid, can be requested via our reagents
website (http://mrcppureagents.dundee.ac.uk/reagents-from-paper/
rouse-paper-1). A list of plasmids, oligonucleotides and peptides
used in this study is shown in Table EV1.
Reagents
Iodoacetamide (I1149), microcystin-LR solution (33893) and Phos-
phatase Inhibitor Cocktail-2 (P5726) solution were all purchased
from Sigma. Universal Nuclease for Cell Lysis (88702) was
purchased from Thermo Fisher Scientific and EDTA-free Protease
Inhibitor Cocktail (11873580001) from Roche. All peptides were
purchased from Peptides & Elephants.
Antibodies
The following antibodies were raised by the Division of Signal
Transduction Therapy at the University of Dundee in sheep and
purified against the relevant antigens: anti-CDKL5 (S957D; raised
against amino acids 350–650 of human CDKL5 expressed in bacteria
using plasmid DU50406; third bleed); anti-MAP1S phospho-Ser900
(SA339; raised against the peptide KKRASRPLpS900ARSEPSE conju-
gated to bovine serum albumin; third bleed); anti-CEP131 phospho-
Ser35 (SA373; raised against the peptide CKKPPVSRRPGpS35AATT
KP conjugated to bovine serum albumin; third bleed); anti-CDKL5
phospho-Tyr171 (SA547; raised against the peptide GNNANYTE
pY171VATRWYR conjugated to bovine serum albumin; third bleed).
Sheep were immunised with each antigen followed by up to five
further injections 28 days apart, with bleeds performed 7 days after
each injection.
Anti-FLAG (M2) and anti-HA antibodies were obtained from
Sigma, and anti-GAPDH (14C10) antibodies were purchased from
Cell Signalling. Secondary anti-sheep, anti-mouse and anti-rabbit
HRP-conjugated antibodies were purchased from Life Technologies
and were used at 1:5,000–1:10,000 dilutions, for 1 h at room
temperature. Anti-pTyr antibodies (4G10) were from Merck.
Cell culture
All cells were kept at 37°C under humidified conditions with 5%
CO2. HEK293, HEK293T and U2OS Flp-In T-Rex (FRT) cells were
grown in DMEM supplemented with 10% (v/v) foetal bovine
serum, 100 U/ml penicillin, 100 lg/ml streptomycin, 1% (v/v) L-
glutamate (GIBCO, Invitrogen), 1% (v/v) sodium pyruvate and 1%
(v/v) non-essential amino acids. U2OS FRT cells were maintained in
10 lg/ml blasticidin. Hygromycin (100 lg/ml) was used to select
for the integration of constructs in Flp-In recombination sites.
Cell lysis, immunoprecipitation, SDS–PAGE and Western blotting
Cells were lysed in a 50 mM Tris/HCl (pH 7.4) buffer containing
0.27 M sucrose, 150 mM NaCl, 1% (v/v) Triton X-100, 0.5% (v/v)
Nonidet NP-40 and 0.1% (v/v) 2-mercaptoethanol. Lysis buffer was
supplemented with a protease inhibitor cocktail (cOmpleteTM, EDTA-
free Protease Inhibitor Cocktail), benzonase (Novagen, 50 U/ml),
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microcystin-LR (Cat. Number, 33893, Sigma) at a final concentra-
tion of 10 ng/ml and phosphatase inhibitor cocktail-2 (P5726,
Merck) at 1% (v/v). Protein extracts were then incubated for
30 min at 4°C and clarified by centrifugation at 17,000 g in a refrig-
erated tabletop centrifuge. To immunoprecipitate endogenous
CDKL5, sheep polyclonal antibodies were incubated overnight with
protein G-agarose (from Expedeon; number APG 0100) at 1 lg anti-
body per 10 ll of settled beads, and then washed twice in PBS.
Approximately 100–500 lg of whole-cell extracts were incubated
with 10 ll (settled) of CDKL5-containing beads for 2–3 h at 4°C. For
anti-FLAG or anti-HA immunoprecipitations, approximately 10 ll
(settled volume) of the following resins was used per 1 mg extract:
FLAG-M2 agarose (Sigma-Aldrich; F1804) or HA-agarose (Sigma-
Aldrich; A2095) beads for 2–3 h at 4°C. Precipitates were washed
three times with lysis buffer and once in cold PBS before boiling at
95°C in LDS–PAGE sample buffer (Thermo Fisher) containing 5%
(v/v) 2-mercaptoethanol. Samples were resolved in 4–12% Bis–Tris
SDS–PAGE gradient gels (NuPAGE, Thermo Fisher).
For Western blotting with phospho-specific MAP1S pSer900 and
CEP131 pSer35 antibodies, the antibodies were diluted in 5% (w/v)
non-fat dry milk in TBS-Tween (0.2% v/v) at a final concentration
of 0.2 lg/ml and supplemented with 10 lg/ml of the corresponding
non-phospho peptide; this mixture was incubated for 1 h at room
temperature. Membranes were incubated overnight at 4°C with the
relevant antibody:non-phosphopeptide mixture. Rabbit anti-sheep
HRP-conjugated secondary antibodies were used at a 1:5,000 dilu-
tion, for 1 h at room temperature.
Transfections
Unless otherwise stated, HEK293 cells were transfected using the
calcium phosphate transfection protocol. HEK293 cells were seeded
at 20–30% confluency into 15-cm plates and transfected 24 h later.
Briefly, for each transfection around 1 ml of 2× HEPES-buffered
saline (HBS) solution was mixed dropwise with 1 ml of a solution
containing 122 ll 2 M calcium chloride and the appropriate amount
of plasmid DNA: 10 lg of DNA when only one plasmid was used, or
5 lg each when cells were co-transfected with two different plas-
mids. The transfection mixture was added dropwise on top of cells,
and plates were incubated for another 24 h before being harvested
in cold PBS buffer and lysed immediately after (as stated below). To
prepare 2× HBS solution, sodium phosphate dibasic heptahydrate
from Sigma-Aldrich (cat. Number 431478) was used.
CRISPR-mediated disruption of CDKL5 in U2OS Flp-In T-REx cells
In order to knock out CDKL5 from cells, we used a modified Cas9
D10A double nickase system (Ran et al, 2013) that requires the pres-
ence of two appropriately offset single-guide RNA pairs. We identified
two sgRNA sequences in exon 5 of human CDKL5 gene separated by
nine nucleotides, as shown in Appendix Fig S1. Single-guide RNA
CDKL5 sense and single-guide RNA CDKL5 antisense sequences were
cloned in their respective plasmids to generate pBABED-PURO-U6-
CDKL5-sense and pX335-CAS9 D10A-CDKL5-antisense. 1 lg of each
plasmid was used to transfect U2OS FRT cells. 24 h post-transfection,
medium was replaced with fresh medium containing 2 lg/ml puro-
mycin and cells were allowed to grow for another 48 h in selection
conditions. Approximately 3,000 cells were then seeded into 15 cm
plates and allowed to grow until they generated visible colonies, and
60 viable individual colonies were picked and expanded. To screen
for the loss of CDKL5 expression in 35 of these clones, cultures were
lysed and CDKL5 was immunoprecipitated using sheep polyclonal
CDKL5 antibodies (S957D). Precipitates were then immunoblotted,
and loss of CDKL5 was confirmed using both a sheep polyclonal
CDKL5 antibody and a mouse monoclonal antibody (D-12, Santa Cruz
Biotechnologies). Five individual clones that showed no detectable
CDKL5 protein in immunoprecipitations and Western blotting were
selected, and genomic DNA around exon 5 was amplified by PCR
using plasmids CDKL5-KO-FWD and CDKL5-KO-REV, cloned using
the Strataclone PCR cloning kit (Stratagene) and sequenced using T7
and T3 oligonucleotides. Two clones (CDKL5D-7 and CDKL5D-13)
lacked a wild-type CDKL5 allele but instead harboured frameshift
mutations in leading to missense and/or premature stop codons
(Appendix Fig S1).
Generation of stable cell lines using the Flp-In T-Rex system
To generate U2OS Flp-In T-REx cells stably expressing CDKL5, cells
were co-transfected with 9 lg of POG44 Flp-recombinase expression
vector (Thermo Fisher) and 1 lg of pcDNA5 FRT/TO-CDKL5, using
GeneJuice Transfection Reagent (Millipore). Around 48 h after
transfection, cells were selected in the presence of 100 lg/ml hygro-
mycin and 10 lg/ml blasticidin in the medium. Ten to 12 days later,
surviving colonies were pooled together and resulting cultures were
analysed for the expression of CDKL5 after induction with increas-
ing amounts of tetracycline hydrochloride (T3383, Sigma-Aldrich).
Phosphoproteomic analysis
The global phosphoproteomics mass spectrometry data relating to
Figs 1 and 2 have been deposited to the ProteomeXchange Consor-
tium via the PRIDE partner repository (Jarnuczak & Vizcaino, 2017)
with the dataset identifier PXD009374.
Protein extraction and digestion for mass spectrometry
Three biological replicates for both CDKL5 knockout U2OS cells
(clone 13) and the same cells in which CDKL5 was reintroduced
were lysed in 8 M urea and 50 mM triethylammonium bicarbonate
(TEAB; pH 8.5) and sonicated, and protein quantification was deter-
mined using the BCA Protein Assay Kit (Pierce Protein). Approxi-
mately 5 mg of protein extract for each sample was reduced by
adding 5 mM Tris(2-carboxyethyl)phosphine (TCEP) for 30 min at
room temperature, and cysteines were alkylated by adding 20 mM
iodoacetamide for 30 min in the dark. Samples were then diluted to
1 M urea and digested overnight at 37°C by adding porcine trypsin
(1:50, w/w; Pierce). Peptides were desalted and concentrated via
C18 SPE on Sep-Pak cartridges (Waters).
Phosphopeptide enrichment for global phosphoproteomic analyses
Phosphopeptide enrichment was similar to previously described
(Larsen et al, 2005; Trost et al, 2009, 2012; Lai et al, 2015). Tryptic
peptides (5 mg per TMT channel) were resuspended in 1 ml of 2 M
lactic acid/50% (v/v) acetonitrile and centrifuged 15,000 × g for
20 min. Supernatants were placed in an Eppendorf LoBind Tube
containing 24 mg of titanium dioxide beads (GL Sciences) and
vortexed for 1 h at room temperature. Beads were washed twice
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with 2 M lactic acid/50% (v/v) acetonitrile and once with 0.1%
(v/v) TFA in 50% (v/v) acetonitrile. Phosphopeptides were eluted
twice with 150 ll of 60 mM ammonium hydroxide (pH > 10.5),
then acidified with 40 ll of 20% (v/v) formic acid and desalted via
C18 Macro SpinColumns (Harvard Apparatus).
Labelling tryptic peptides with tandem mass tags
Isobaric labelling of phosphorylated peptides was performed using
the 6-plex tandem mass tag (TMT) reagents (Thermo Fisher). TMT
reagents (0.8 mg) were dissolved in 41 ll of acetonitrile, and 20 ll
was added to the corresponding fractions, previously dissolved in
50 ll of 50 mM TEAB, pH 8.5. The reaction was quenched by addi-
tion of 4 ll of 5% hydroxylamine after 1-h incubation at room
temperature. Labelled peptides were combined, acidified with
200 ll of 1% TFA (pH ~ 2) and concentrated using C18 SPE on Sep-
Pak cartridges (Waters). Labelling efficiency was tested for each
TMT-labelled sample and was > 95%.
High-pH reversed-phase chromatography fractionation
TMT-labelled phosphorylated peptides were combined at equal
amounts for each channel and subjected to HPRP. Labelled
peptides were solubilized in 20 mM ammonium formate (pH 8.0)
and separated on a Gemini C18 column (250 × 3 mm, 3 lm C18
110 A˚ pore size; Phenomenex). Using a DGP-3600BM pump
system equipped with a SRD-3600 degasser (Thermo Fisher), a
40 min gradient from 1 to 90% acetonitrile (flow rate of 0.25 ml/
min) separated the peptide mixtures into a total of 40 fractions.
The 40 fractions were merged into 12 samples, acidified with 1%
(v/v) TFA (pH ~ 2), desalted via C18 Macro SpinColumns (Har-
vard Apparatus), dried under vacuum centrifugation and resus-
pended in 2% (v/v) ACN/0.1% (v/v) TFA for LC-MS/MS
analysis.
Liquid chromatography and tandem mass spectrometry (LC-MS/MS)
Fractions were separated on an Ultimate 3000 Rapid Separation LC
Systems chromatography (Thermo Fisher) with a C18 PepMap,
serving as a trapping column (2 cm × 100 lm ID, PepMap C18,
5 lm particles, 100 A˚ pore size) followed by a 50-cm EASY-Spray
column (50 cm × 75 lm ID, PepMap C18, 2 lm particles, 100 A˚
pore size; Thermo Fisher) with a linear gradient of 2.4–20% (v/v;
ACN, 0.1% (v/v) formic acid (FA)) over 175 min followed by a
step from 20 to 28% (v/v) ACN, 0.1% (v/v) FA over 30 min, both
segments had a flow rate at 300 nl/min. Mass spectrometric analy-
sis was performed on an Orbitrap Fusion Tribrid mass spectrome-
ter (Thermo Fisher) operated in “Top Speed” data-dependent,
positive ion mode. FullScan spectra were acquired in a range from
400 to 1,600 m/z, at a resolution of 120,000 (at 200 m/z), with an
automated gain control (AGC) of 300,000 ions and a maximum
injection time of 50 ms. Precursors with a charge state of 1 were
excluded. Intensity threshold for MS/MS fragmentation was set to
104 counts. The most intense precursor ions were isolated with a
quadrupole mass filter width of 1.6 m/z, and HCD fragmentation
was performed with a one-step collision energy of 37.5% and acti-
vation Q of 0.25. MS/MS fragment ions were measured in the
Orbitrap mass analyser with a 50,000 resolution at 200 m/z. The
detection of MS/MS fragments was set up as the “Universal
Method”, using a maximum injection time of 300 ms and a maxi-
mum AGC of 2,000 ions.
Data processing and quantitative data analysis of TMT data
Protein identification and TMT quantification were performed using
MaxQuant version 1.5.1.7 (Cox & Mann, 2008). Trypsin/P was set
as protease; stable modification: carbamidomethyl (C); variable
modifications: oxidation (M), acetyl (protein N-terminal), phospho
(STY); maximum eight modifications per peptide and two missed
cleavages. Searches were conducted using a combined UniProt-
TrEMBL Homo sapiens database with isoforms downloaded on July
15, 2015, plus common contaminants (42,095 sequences). Identifi-
cations were filtered at a 1% FDR at the peptide level, accepting a
minimum peptide length of 5. TMT intensities were extracted,
normalized for each condition and were used for downstream analy-
ses in Perseus 1.5.3.1 (Cox & Mann, 2012). Student’s t-test (two-
tailed, homoscedastic) was performed on the normalized TMT
intensities, and phosphopeptides with P < 0.05 and a fold change
> 1.5 were considered significantly altered in abundance between
the samples.
Motif-X and network analysis
Significant mass spectrometry hits (> 1.5-fold change, P < 0.05)
were analysed using UniProt, motif-x and the STRING database.
Motif-x software (Schwartz & Gygi, 2005) was used with pre-aligned
sequence tags around the phosphosites. Following parameters were
applied: occurrences 10; significance P < 0.0001. String database
v10.0 (Szklarczyk et al, 2015) analysis was performed using default
parameters (medium confidence). The networks were exported into
Cytoscape (Shannon et al, 2003).
Extracted ion chromatogram (XIC) analysis
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository (Jar-
nuczak & Vizcaino, 2017) with the dataset identifier PXD009327.
In-gel digest
Bands from SDS–PAGE gel were cut out with a scalpel and
destained in 30% (v/v) ACN (Merck: 1.00029.1000), 25 mM
ammonium bicarbonate (Sigma: 09830) and incubated in an
ultrasonic bath for 30 min. This step was repeated until all gel
pieces appeared clear. Afterwards, the gel pieces were dehydrated
using 100% (v/v) ACN for 15 min at room temperature. The
acetonitrile was removed, and proteins were reduced and alky-
lated using 10 mM TCEP (Sigma: C4706) and 25 mM 2-chloroace-
tamide (CAA, Sigma: C0267) in 50 mM ammonium bicarbonate
for 45 min at room temperature in the dark. Gel pieces were
dehydrated afterwards as described above, and supernatant was
removed. Trypsin/LysC (Promega: V5111) was resuspended in
100 mM ammonium bicarbonate to a concentration of 0.05 lg/ll,
and 20 ll (= 1 lg) was added to each vial containing the dehy-
drated gel pieces. Acetonitrile was added to a final concentration
of 10% (v/v), and protease digest was carried out overnight at
37°C and 300 rpm using a Thermomix (Eppendorf). Peptides
were extracted in three steps: 1% (v/v) FA (Merck:
5.33002.0050); 60% (v/v) ACN, 1% (v/v) FA; and as last step
100% (v/v) ACN. Extraction was carried out for 15 min using an
ultrasonic bath. After each step, the respective supernatant was
removed, combined into a tube and freeze-dried (ScanVac Cool-
Safe) overnight.
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C18 clean-up
StageTips were prepared in-house using C18 discs (Empore, Sigma:
66883), with a total of two C18 plugs per tip. Freeze-dried peptides
were resuspended in TA2 (2% (v/v) ACN, 0.1% (v/v) TFA (Merck:
1.08262.0025)). StageTip was activated using 100% (v/v) acetoni-
trile and equilibrated using 0.1% (v/v) TFA. Peptides were bound
to the C18 StageTip, desalted twice using 0.1% (v/v) TFA and
eluted with 70% (v/v) ACN, 0.1% (v/v) TFA. Eluate was freeze-
dried overnight.
TMT labelling
TMT-10plex (Thermo Fisher: 90110) labels (0.8 mg) were resus-
pended in 100 ll anhydrous ACN (Sigma: 271004), vortexed and
incubated for 5 min at room temperature. Freeze-dried eluted
peptides were resuspended in 80 ll 100 mM TEAB (Thermo Fisher:
90114) and incubated in an ultrasonic bath for 15 min. Seventy
microlitres of each sample was combined with 30 ll of the respec-
tive TMT10plex label (see Table EV2). TMT reaction was carried
out at room temperature for 2 h. An aliquot of 10 ll of each sample
was taken, and the reaction was stopped by addition of 50% (w/v)
hydroxylamine (Sigma: 467804) to a final concentration of 5%
(v/v). Stopped TMT reactions were combined and freeze-dried
overnight.
Mass spectrometry
Freeze-dried TMT-labelled peptides were resuspended in 20 ll TA2
and incubated in an ultrasonic bath for 15 min. Mass spectrometry
was carried out on an Orbitrap Velos (Thermo Fisher) coupled to an
Ultimate 3000 HPLC system (Thermo Fisher). One microlitre of
peptides was injected and desalted for 5 min on an Acclaim PepMap
100 C18 column (5 lm particle size, 100 lm inner diameter, 2 cm
length, 100 A˚ pore size, Thermo Fisher) using 3% (v/v) ACN, 0.1%
(v/v) TFA at a flow rate of 5 ll/min. Afterwards, peptides were
separated on an Acclaim PepMap 100 C18 column (2 lm particle
size, 75 lm inner diameter, 50 cm length, 100 A˚ pore size, Thermo
Fisher) using a two-buffer gradient system. Buffer component A was
0.1% (v/v) FA, Buffer component B consisted of 80% (v/v) ACN,
0.08% (v/v) FA. Peptides were eluted using a gradient from 3 to
35% (v/v) B over 101 min. This was followed by a gradient to 99%
(v/v) B within 5 min and was held for 3 min. Afterwards, the
column was washed for 5 min with 3% (v/v) B. Flow rate in all
steps was 300 nl/min. Temperature of the column oven was set to
45°C. HPLC was coupled to the Orbitrap via an EASY-Spray ESI
source (Thermo Fisher). Orbitrap acquired data in Nth order double
play mode, scanning between m/z 400 and 1,600 with the top 20
most intense m/z features undergoing HCD fragmentation (mini-
mum signal required: 2,000; isolation width: 2.0; normalized colli-
sion energy 35.0, activation time: 0.1). Internal calibration was
performed using a lock mass at 445.120024 m/z.
Data analysis
Raw files were searched using the Andromeda search engine inte-
grated into MaxQuant (Cox et al, 2011; version 1.5.8.3) against a
Uniprot human database downloaded on 08/11/2017 (20,239
sequences). Standard MaxQuant search parameters for Orbitrap data
were used as follows: 4.5 ppm precursor tolerance with MS/MS
tolerance of 20 ppm. Protease was specified as trypsin/P, fixed
modification was set as carbamidomethylation of cysteine, and
variable modifications were oxidation of methionine, protein N-
terminal acetylation and phosphorylation of serine and threonine.
Isobaric labelling was specified as TMT10plex, with omission of
TMT-126 label. Reporter ion mass tolerance was set to 0.003 Da,
and parent ion fraction (PIF) cut-off was set to 75%. Cut-offs for
posterior error probabilities of peptide to spectrum matches, peptide
and protein identifications were set to 1 per cent. MaxQuant data
were analysed using an R-script with additional libraries ggplot2
(Wickham, 2009), reshape2 (Wickham, 2007) and VSN (Huber
et al, 2002; Computer Code EV1; Appendix Fig S4). In brief, isotopi-
cally corrected reporter intensities were normalized and transformed
using variance stabilizing normalization (VSN; Huber et al, 2002,
2003), and then, data were tested for differences in the mean of the
groups using a t-test. Multiple testing was controlled for by lowering
the significance threshold of a = 0.05 to a = 0.00833 [six t-tests,
Bonferroni method (Computer Code EV1)].
Measuring peptide kinase activity in CDKL5 immunoprecipitates
Cells were lysed in ice-cold wash buffer (50 mM HEPES (pH 7.5),
1% Triton X-100, 0.3 M sucrose, 300 mM NaCl) supplemented with
10 mM iodoacetamide, 10 ng/ml microcystin-LR, 2% (v/v) phos-
phatase inhibitor cocktail supplemented with a protease inhibitor
cocktail (cOmpleteTM, EDTA-free Protease Inhibitor Cocktail) and
500 U/ml universal nuclease which were all added immediately
before lysis. Cell debris was broken up using a needle and cleared
by centrifugation at 20,800 g at 4°C. Extract protein concentration
was quantified by using PierceTM BCA Protein Assay Kit (Thermo
Scientific 23225) in 96-well plates. For measuring kinase activity,
extracts (1.0–2.5 mg) from HEK293 cells transiently expressing
CDKL5-FLAG were incubated with 10 ll (settled) anti-FLAG agarose
M2 affinity gel (Sigma-Aldrich) for 1 h. Beads were washed three
times (15 min each) in wash buffer (without protease inhibitors)
containing 1 M NaCl and then twice in kinase buffer (50 mM Tris
7.5, 10 mM MgCl2, 0.1 mM EGTA). Beads were suspended in 15 ll
kinase buffer containing 0.15 mM peptide substrate and 0.1% (v/v)
2-mercaptoethanol. Reactions were initiated with 5 ll of [c-32P]-
ATP (final ATP concentration 0.1 mM) and incubated for 30 min at
30°C before being stopped by the addition of 10 ll of 0.1M EDTA.
After centrifugation at 500 × g, supernatants (30 ll) were spotted
onto P81-cation exchange (phosphocellulose) paper, and papers
were washed in 75 mM orthophosphoric acid until background
counts were at a minimum, dried in acetone and placed in scintilla-
tion counter to detect 32P incorporation by Cerenkov counting. The
remaining beads were boiled in LDS sample buffer and subjected to
SDS–PAGE followed by Western blotting to monitor CDKL5 abun-
dance.
Protein sequence alignments
Protein sequences from different species were obtained from
Uniprot: http://www.uniprot.org/ or Protein Blast: https://blast.ncb
i.nlm.nih.gov/Blast.cgi?PAGE=Proteins. Sequences to be aligned
were introduced in Clustal Omega: https://www.ebi.ac.uk/Tools/
msa/clustalo/, and the resulting alignments were then pasted in
Boxshade server: https://embnet.vital-it.ch/software/BOX_form.
html. Fifteen residues from each side of the RPXSA motif are shown
for clarity in the alignments.
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Statistical analysis
All bar graphs and box plots in Figs 4–7 and EV2, EV3 and EV5
were generated using GraphPad Prism software using standard
settings (version 5.0b, GraphPad Software, Inc.)
Data availability
The global phosphoproteomics mass spectrometry data relating to
Figs 1 and 2 have been deposited to the ProteomeXchange Consor-
tium via the PRIDE partner repository (Jarnuczak & Vizcaino, 2017)
with the dataset identifier PXD009374. The mass spectrometry
proteomics data relating to the extracted ion chromatograms in
Fig 5 have been deposited to the ProteomeXchange Consortium via
the PRIDE partner repository (Jarnuczak & Vizcaino, 2017) with the
dataset identifier PXD009327.
Expanded View for this article is available online.
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